VGX-1027

VGX-1027
Identifiers
  • 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H11NO3
Molar mass205.213 g·mol−1
3D model (JSmol)
  • C1C(ON=C1C2=CC=CC=C2)CC(=O)O
  • InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
  • Key:MUFJHYRCIHHATF-UHFFFAOYSA-N

VGX-1027 (GIT-27) is a drug which acts as an immunomodulator. It acts by blocking downstream signalling of the Toll-like receptors TLR2, TLR4 and TLR6, and thereby reducing production of various cytokines, including interleukins and TNF-α. In animal studies it has antiinflammatory effects and has been investigated for conditions such as arthritis and lung inflammation.[1][2][3][4][5][6]

References

  1. ^ Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. (June 2007). "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models". Clinical Immunology. 123 (3): 311–23. doi:10.1016/j.clim.2007.03.004. PMID 17449326.
  2. ^ Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, et al. (June 2013). "Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice". Endocrinology. 154 (6): 2144–55. doi:10.1210/en.2012-2080. PMID 23568555.
  3. ^ Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL, et al. (May 2015). "Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway". Cell Death & Disease. 6 (5): e1752. doi:10.1038/cddis.2015.125. PMC 4669704. PMID 25950482.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. (March 2016). "Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects". Clinical Pharmacology in Drug Development. 5 (2): 91–101. doi:10.1002/cpdd.193. PMID 27138022. S2CID 22577185.
  5. ^ Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. (January 2019). "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness". European Journal of Pharmacology. 842: 373–383. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292. PMID 30419239. S2CID 53292202.
  6. ^ Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. (November 2019). "The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice". Life Sciences. 237 116930. doi:10.1016/j.lfs.2019.116930. PMID 31610190. S2CID 204702143.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.